ClinicalTrials.gg
RecruitingNCT06613256JEDI-2Updated Sep 25, 2024

Characterisation of Endothelial Cells in Different Inflammatory Pathologies

An observational study in Sepsis and Vasoplegia, sponsored by Royal Surrey County Hospital NHS Foundation Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-25.

Sponsored by Royal Surrey County Hospital NHS Foundation Trust · Observational

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 3 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
105
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to characterise changes in gene expression in endothelial cells in patients with either sepsis or post major abdominal surgery.

The main question we plan to answer is: 'What molecular pathways are differentially expressed during inflammatory pathologies?'

Read the detailed description

The immune system is a complex network of cells and molecules that protects the body from infection and injury. When the immune system is activated, it produces inflammation, which is a natural response to help heal the body. However, too much inflammation can be harmful and lead to serious complications, such as sepsis, low blood pressure, organ failure and death.

The interaction of cells that line the blood vessels (endothelial cells, EC) with the immune system, is believed to be the root cause of these symptoms. When exposed to inflammation, the instructional molecules (RNA) inside the EC change. This leads to a change of operation promoting the severe symptoms previously mentioned.

Researchers have developed new safe techniques to collect these cells from the blood vessels of patients to study disorders like diabetes, heart disease and stroke. This technique involves gently inserting a metal guidewire into an arm vein to collect ECs.

This study plans to collect ECs from patients undergoing surgery or admitted to intensive care. We also plan to collect control samples from healthy volunteers. Samples will be collected over the duration of the patients to RSFT. The RNA will be removed from the cells and counted to highlight changes in instructions in the cells.

Data from this study will potentially highlight new pathways involved in inflammation and help classify how some patients will react to current treatments. To obtain this data, this study will be split into 2 parts. Part 1 focuses on collecting one sample from a patient when they are at their most unwell states and comparing that to a sample from a healthy person. Part 2 will focus on key mRNA molecules identified during Part 1 and identifying how their expression changes over time.

02

Conditions studied

  • Sepsis
  • Vasoplegia

Browse trials for

03

In context

Sepsis

2,416 studies on the registry are indexed under Sepsis; 541 are open to participants now.

This study's planned enrollment of 105 is below the median of 150 across 1,162 observational studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

Royal Surrey County Hospital NHS Foundation Trust is the lead sponsor of 35 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Surgical cohort This cohort will predominantly be made up predominantly of patients undergoing major abdominal surgery (HPB, Gynae Onc and Colorectal) requiring recovery in ICU as part of their cancer treatment.

Critically unwell cohort This cohort will be made up of emergency admissions to ICU for patients requiring additional organ support.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy volunteer

  • Adult ≥ 18 years
  • Able and willing to give consent

Surgical patients

  • Adult ≥ 18 years
  • Patients admitted to RSFT for planned major surgery

Critically ill patients

  • Adult ≥ 18 years
  • Emergency admission to ICU at RSFT
  • Meets the sepsis 3.0 definition

Exclusion criteria

Exclusion Criteria:

Healthy volunteer

  • Not currently a patient within the hospital
  • Absence of inflammatory diseases and disorders including but not limited to arthritis, peripheral artery disease, vasculitis, diabetes, cardiovascular disease and CKD.
  • Not on immunomodulatory medications, such as
  • History of recent major trauma within the last 2 months (e.g., surgery or injury requiring hospitalisation)

Surgical patients

  • Patients with restricted liberty, prisoners or under legal protection
  • Anticipated prohibitively difficult venous cannulation
  • Presenting with inflammatory diseases and disorders including but not limited to arthritis, peripheral artery disease, vasculitis, sepsis, diabetes with end organ damage, cardiovascular disease and CKD
  • Currently prescribed immunomodulatory medication or
  • Received chemotherapy within 2 weeks of predicted sampling
  • Receiving vasopressor support prior to surgery
  • History of recent major trauma within the last 2 months (e.g., surgery or injury requiring hospitalisation)

Critically ill patients

  • Patients with restricted liberty, prisoners or under legal protection• Anticipated prohibitively difficult venous cannulation
  • Presenting with inflammatory diseases and disorders including but not limited to arthritis, peripheral artery disease, vasculitis, diabetes with end organ damage, cardiovascular disease and CKD.
  • Currently prescribed immunomodulatory medication or immunocompromised
  • Received chemotherapy within 2 weeks of predicted sampling.
  • History of recent major trauma within the last 2 months (e.g., surgery or injury requiring hospitalisation)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
105 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Part 1 - control patients

    25 healthy volunteers 1 X Endothelial cell biopsy

    Other: Endothelial cell biopsy

  • Part 1 - surgical patients

    20 surgical patients 1 X Endothelial cell biopsy Samples collected at 24 hours post knife to skin to capture peak inflammation

    Other: Endothelial cell biopsy

  • Part 1 - sepsis patients

    20 sepsis patients 1 X Endothelial cell biopsy Samples collected on admission to ICU

    Other: Endothelial cell biopsy

  • Part 2 - surgical patients

    20 surgical patients 3 X Endothelial cell biopsy Samples collected pre-surgery, 24 hours and 48 hours post knife to skin

    Other: Endothelial cell biopsy

  • Part 2 - sepsis patients

    20 sepsis patients 3 X Endothelial cell biopsy Samples collected on admission, 24 hours and 48 hours post admission to ICU

    Other: Endothelial cell biopsy

Interventions

  • OtherEndothelial cell biopsy

    Endothelial cell sample collected from the antecubital fossa of patients. A vein in the antecubital fossa is cannulated with a 20 g valveless cannula. A metal guidewire is then passed into the vessel to collect endothelial cells for analysis

06

What researchers measure

Primary outcomes

  1. Differential gene expression in endothelial cells

    Using RNA extracted from the two patient cohorts and controls in part 1, we plan to use RNA-SEQ to identify differentially expressed genes. Once we have identified genes we believe to be critically involved with endothelial dysfunction, we will then perform serial sampling on an additional two groups of patients and using qRT-PCR to analyse gene expression changes.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06613256
Lead sponsor
Royal Surrey County Hospital NHS Foundation Trust
Collaborators
University of Surrey
Responsible party
Sponsor
First posted
Sep 25, 2024
Start date
Jul 16, 2024
Primary completion
Jul 17, 2026 (estimated)
Completion
Nov 12, 2026 (estimated)
Last update
Sep 25, 2024

Study contacts

Ben Creagh-Brown, BM, PhD
Contact
bencb@nhs.net
+44 (0)1483 688 660
Charlie Piercy, MSc
Contact
charles.piercy@nhs.net
+44 (0)1483 688 660

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion